{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:12:51Z","timestamp":1784113971529,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08210-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:34:31Z","timestamp":1781098471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term benzodiazepine use is associated with poorer cognitive function in schizophrenia: findings from the SALT-C cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Caiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"8210_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Marques TR, Howes OD. Schizophrenia\u2014an overview. JAMA Psychiatry. 2020;77(2):201\u201310. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3360.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"8210_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and burden of schizophrenia: findings from the Global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195\u2013203. https:\/\/doi.org\/10.1093\/schbul\/sby058.","journal-title":"Schizophr Bull"},{"key":"8210_CR3","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.scog.2022.100249","volume":"29","author":"PD Harvey","year":"2022","unstructured":"Harvey PD, Bosia M, Cavallaro R, Howes OD, Kahn RS, Leucht S, et al. Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art. Schizophr Res: Cognition. 2022;29:100249. https:\/\/doi.org\/10.1016\/j.scog.2022.100249.","journal-title":"Schizophr Res: Cognition"},{"issue":"5","key":"8210_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/archpsyc.64.5.532","volume":"64","author":"D Dickinson","year":"2007","unstructured":"Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64(5):532\u201342. https:\/\/doi.org\/10.1001\/archpsyc.64.5.532.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"8210_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/070674371405900104","volume":"59","author":"TK Rajji","year":"2014","unstructured":"Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry. 2014;59(1):13\u201317. https:\/\/doi.org\/10.1177\/070674371405900104.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"8210_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-pharmtox-051921-093250","volume":"63","author":"DC Javitt","year":"2023","unstructured":"Javitt DC. Cognitive impairment associated with schizophrenia: from pathophysiology to treatment. Annu Rev Pharmacol Toxicol. 2023;63(1):119\u201341. https:\/\/doi.org\/10.1146\/annurev-pharmtox-051921-093250.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8210_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-642-25758-2_2","volume":"213","author":"RS Keefe","year":"2012","unstructured":"Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;213:11\u201337.","journal-title":"Handb Exp Pharmacol"},{"issue":"400","key":"8210_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.0065-1591.2000.007s021[dash]3.x","volume":"101","author":"PF Liddle","year":"2000","unstructured":"Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand Suppl. 2000;101(400):11\u201316. https:\/\/doi.org\/10.1111\/j.0065-1591.2000.007s021[dash]3.x.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"Suppl, 14","key":"8210_CR9","first-page":"4","volume":"68","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP. The costs of schizophrenia. J Clin Psychiatry. 2007;68(Suppl, 14):4\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"8210_CR10","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol. Psychiatry. 2023;28(5):1902\u201318. https:\/\/doi.org\/10.1038\/s41380-023-01949-9.","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"8210_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.14740\/jocmr4798","volume":"14","author":"T Shimada","year":"2022","unstructured":"Shimada T, Kobayashi G, Saeki Y, Mizukoshi C, Chikazawa K, Nokura K, et al. A retrospective study on the relationship between cognitive function and social function in patients with schizophrenia. J Clin Med Res. 2022;14(9):348\u201356. https:\/\/doi.org\/10.14740\/jocmr4798.","journal-title":"J Clin Med Res"},{"key":"8210_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neubiorev.2019.07.020","volume":"105","author":"TF Halverson","year":"2019","unstructured":"Halverson TF, Orleans-Pobee M, Merritt C, Sheeran P, Fett A-K, Penn DL. Pathways to functional outcomes in schizophrenia spectrum disorders: meta-analysis of social cognitive and neurocognitive predictors. Neurosci. Biobehav. Rev. 2019;105:212\u201319. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.07.020.","journal-title":"Neurosci. Biobehav. Rev"},{"key":"8210_CR13","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704.","journal-title":"Neuropharmacology"},{"issue":"2","key":"8210_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0447.2009.01356.x","volume":"120","author":"J Moncrieff","year":"2009","unstructured":"Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of internet data. Acta Psychiatr Scand. 2009;120(2):102\u201311. https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01356.x.","journal-title":"Acta Psychiatr Scand"},{"key":"8210_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","volume":"190","author":"S Eum","year":"2017","unstructured":"Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017;190:129\u201335. https:\/\/doi.org\/10.1016\/j.schres.2017.03.034.","journal-title":"Schizophr Res"},{"issue":"9","key":"8210_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","volume":"178","author":"YB Joshi","year":"2021","unstructured":"Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic medication burden\u2013associated cognitive impairment in schizophrenia. AJP. 2021;178(9):838\u201347. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081212.","journal-title":"AJP"},{"issue":"2","key":"8210_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4088\/JCP.v65n0202","volume":"65","author":"RE Clark","year":"2004","unstructured":"Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151\u201355. https:\/\/doi.org\/10.4088\/JCP.v65n0202.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"8210_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3\u201378. https:\/\/doi.org\/10.1177\/0269881119889296.","journal-title":"J Psychopharmacol"},{"key":"8210_CR19","doi-asserted-by":"publisher","unstructured":"Chakos MH, et al. Special section on CATIE baseline data: baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Serv. 2006;57(8):1094\u20131101. https:\/\/doi.org\/10.1176\/ps.2006.57.8.1094.","DOI":"10.1176\/ps.2006.57.8.1094"},{"issue":"8","key":"8210_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1176\/ps.62.8.pss6208_0908","volume":"62","author":"CS Wu","year":"2011","unstructured":"Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatr Serv. 2011;62(8):908\u201314. https:\/\/doi.org\/10.1176\/ps.62.8.pss6208_0908.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"8210_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37\u201348. https:\/\/doi.org\/10.2165\/00023210-200418010-00004.","journal-title":"CNS Drugs"},{"issue":"7","key":"8210_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/arclin\/acx120","volume":"33","author":"SF Crowe","year":"2018","unstructured":"Crowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an Updated meta-analysis. Archives Clin Neuropsychol. 2018;33(7):901\u201311. https:\/\/doi.org\/10.1093\/arclin\/acx120.","journal-title":"Archives Clin Neuropsychol"},{"issue":"6","key":"8210_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/0269881106072386","volume":"21","author":"C Haw","year":"2007","unstructured":"Haw C, Stubbs J. Benzodiazepines \u2014 a necessary evil? A survey of prescribing at a specialist Uk psychiatric hospital. J Psychopharmacol. 2007;21(6):645\u201349. https:\/\/doi.org\/10.1177\/0269881106072386.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"8210_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000525988","volume":"28","author":"SPG Zetsen","year":"2022","unstructured":"Zetsen SPG, Schellekens AFA, Paling EP, Kan CC, Kessels RPC. Cognitive functioning in long-term benzodiazepine users. Eur Addict Res. 2022;28(5):377\u201381. https:\/\/doi.org\/10.1159\/000525988.","journal-title":"Eur Addict Res"},{"key":"8210_CR25","doi-asserted-by":"publisher","first-page":"106248","DOI":"10.1016\/j.nbd.2023.106248","volume":"185","author":"JM Lorenz-Guertin","year":"2023","unstructured":"Lorenz-Guertin JM, Povysheva N, Chapman CA, MacDonald ML, Fazzari M, Nigam A, et al. Inhibitory and excitatory synaptic neuroadaptations in the diazepam tolerant brain. Neurobiol Disease. 2023;185:106248. https:\/\/doi.org\/10.1016\/j.nbd.2023.106248.","journal-title":"Neurobiol Disease"},{"key":"8210_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/1569456","volume":"2020","author":"D Nader","year":"2020","unstructured":"Nader D, Gowing L. Is long-term benzodiazepine use a risk factor for cognitive decline? Results of a systematic review. J Addict. 2020;2020:1\u201310. https:\/\/doi.org\/10.1155\/2020\/1569456.","journal-title":"J Addict"},{"issue":"4","key":"8210_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1017\/S1041610219000358","volume":"32","author":"JP Schuster","year":"2020","unstructured":"Schuster JP, Hoertel N, von Gunten A, Seigneurie A-S, Limosin F. Benzodiazepine use among older adults with schizophrenia spectrum disorder: prevalence and associated factors in a multicenter study. Int Psychogeriatrics. 2020;32(4):441\u201351. https:\/\/doi.org\/10.1017\/S1041610219000358.","journal-title":"Int Psychogeriatrics"},{"issue":"1","key":"8210_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-017-0787-9","volume":"268","author":"G Fond","year":"2018","unstructured":"Fond G, Berna F, Boyer L, Godin O, Brunel L, Andrianarisoa M, et al. Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci. 2018;268(1):17\u201326. https:\/\/doi.org\/10.1007\/s00406-017-0787-9.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"8210_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eurpsy.2017.06.004","volume":"45","author":"AP Hulkko","year":"2017","unstructured":"Hulkko AP, Murray GK, Moilanen J, Haapea M, Rannikko I, Jones PB, et al. Lifetime use of psychiatric medications and cognition at 43years of age in schizophrenia in the northern Finland birth cohort 1966. Eur Psychiatr. 2017;45:50\u201358. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.06.004.","journal-title":"Eur Psychiatr"},{"issue":"2","key":"8210_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.pnpbp.2011.11.008","volume":"36","author":"R Kitajima","year":"2012","unstructured":"Kitajima R, Miyamoto S, Tenjin T, Ojima K, Ogino S, Miyake N, et al. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):300\u201306. https:\/\/doi.org\/10.1016\/j.pnpbp.2011.11.008.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"8210_CR31","doi-asserted-by":"publisher","unstructured":"Yu W, Huang J, He S, Zhang L, Shen Y, Li H. Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study. Gen Psychiatry. 2021;34(1):e100289. https:\/\/doi.org\/10.1136\/gpsych-2020-100289.","DOI":"10.1136\/gpsych-2020-100289"},{"issue":"6","key":"8210_CR32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. AJP. 2010;167(6):686\u201393. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09060802.","journal-title":"AJP"},{"key":"8210_CR33","unstructured":"Ashton H. Benzodiazepines: how they work and how to withdraw. 2002 [cited 2026 April 19th]; Available from: https:\/\/www.benzo.org.uk\/manual\/bzcha01.htm."},{"key":"8210_CR34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.schres.2019.10.054","volume":"216","author":"GJ Gil-Berrozpe","year":"2020","unstructured":"Gil-Berrozpe GJ, S\u00e1nchez-Torres AM, Garc\u00eda de Jal\u00f3n E, Moreno-Izco L, Fa\u00f1an\u00e1s L, Peralta V, et al. Utility of the MoCA for cognitive impairment screening in long-term psychosis patients. Schizophr Res. 2020;216:429\u201334. https:\/\/doi.org\/10.1016\/j.schres.2019.10.054.","journal-title":"Schizophr Res"},{"key":"8210_CR35","doi-asserted-by":"publisher","first-page":"114731","DOI":"10.1016\/j.psychres.2022.114731","volume":"316","author":"MC Daderwal","year":"2022","unstructured":"Daderwal MC, Sreeraj VS, Suhas S, Rao NP, Venkatasubramanian G. Montreal cognitive Assessment (MoCA) and digit symbol substitution test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia. Psychiatry Res. 2022;316:114731. https:\/\/doi.org\/10.1016\/j.psychres.2022.114731.","journal-title":"Psychiatry Res"},{"issue":"2","key":"8210_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"1\u20132","key":"8210_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.psychres.2010.05.001","volume":"185","author":"S Tianmei","year":"2011","unstructured":"Tianmei S, Liang S, Yun\u2019ai S, Chenghua T, Jun Y, Jia C, et al. The Chinese version of the Personal and social performance scale (PSP): validity and reliability. Psychiatry Res. 2011;185(1\u20132):275\u201379. https:\/\/doi.org\/10.1016\/j.psychres.2010.05.001.","journal-title":"Psychiatry Res"},{"key":"8210_CR38","volume-title":"Clinical Global impressions. ECDEU Assessment manual for Psychopharmacology (revised)","author":"W Gay","year":"1976","unstructured":"Gay W. Clinical Global impressions. ECDEU Assessment manual for Psychopharmacology (revised). Rockville MD: \u2022 National Institute of Mental Health.-1976; 1976."},{"issue":"4","key":"8210_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatrics Soc. 2005;53(4):695\u201399. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatrics Soc"},{"issue":"3","key":"8210_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s13365-022-01076-1","volume":"28","author":"EE Sundermann","year":"2022","unstructured":"Sundermann EE, Saloner R, Rubtsova A, Nguyen AL, Letendre S, Moore RC, et al. The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV. J Neurovirol. 2022;28(3):410\u201321. https:\/\/doi.org\/10.1007\/s13365-022-01076-1.","journal-title":"J Neurovirol"},{"issue":"3","key":"8210_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/WNF.0000000000000442","volume":"44","author":"B Savi\u0107","year":"2021","unstructured":"Savi\u0107 B, Jeroti\u0107 S, Risti\u0107 I, Zebi\u0107 M, Jovanovi\u0107 N, Russo M, et al. Long-term benzodiazepine prescription during maintenance therapy of individuals with psychosis spectrum disorders\u2014associations with Cognition and Global functioning. Clin Neuropharm. 2021;44(3):89\u201393. https:\/\/doi.org\/10.1097\/WNF.0000000000000442.","journal-title":"Clin Neuropharm"},{"key":"8210_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.schres.2024.02.025","volume":"266","author":"V Makipelto","year":"2024","unstructured":"Makipelto V, Tuulio-Henriksson A, Hakulinen C, Niemel\u00e4 S, L\u00e4hteenvuo M, Wegelius A, et al. Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia. Schizophr Res. 2024;266:118\u201326. https:\/\/doi.org\/10.1016\/j.schres.2024.02.025.","journal-title":"Schizophr Res"},{"issue":"2","key":"8210_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00406-016-0711-8","volume":"267","author":"L Baandrup","year":"2017","unstructured":"Baandrup L, Fagerlund B, Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163\u201371. https:\/\/doi.org\/10.1007\/s00406-016-0711-8.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1\u20133","key":"8210_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.schres.2014.07.006","volume":"158","author":"C Wu","year":"2014","unstructured":"Wu C, Dagg P, Molgat C. A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal cognitive Assessment (MoCA). Schizophr Res. 2014;158(1\u20133):151\u201355. https:\/\/doi.org\/10.1016\/j.schres.2014.07.006.","journal-title":"Schizophr Res"},{"key":"8210_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2018.03.008","volume":"199","author":"Z Yang","year":"2018","unstructured":"Yang Z, Abdul Rashid NA, Quek YF, Lam M, See YM, Maniam Y, et al. Montreal cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. Schizophr Res. 2018;199:58\u201363. https:\/\/doi.org\/10.1016\/j.schres.2018.03.008.","journal-title":"Schizophr Res"},{"issue":"2","key":"8210_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","volume":"165","author":"KH Nuechterlein","year":"2008","unstructured":"Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus cognitive Battery, part 1: test selection, reliability, and validity. AJP. 2008;165(2):203\u201313. https:\/\/doi.org\/10.1176\/appi.ajp.2007.07010042.","journal-title":"AJP"},{"issue":"2","key":"8210_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","volume":"165","author":"RS Kern","year":"2008","unstructured":"Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. The MATRICS Consensus cognitive Battery, part 2: co-norming and standardization. AJP. 2008;165(2):214\u201320. https:\/\/doi.org\/10.1176\/appi.ajp.2007.07010043.","journal-title":"AJP"},{"issue":"12","key":"8210_CR48","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/gps.1811","volume":"22","author":"EJ Bierman","year":"2007","unstructured":"Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman ATF. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriat Psychiatry. 2007;22(12):1194\u2013200. https:\/\/doi.org\/10.1002\/gps.1811.","journal-title":"Int J Geriat Psychiatry"},{"issue":"1","key":"8210_CR49","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12888-024-06335-5","volume":"24","author":"D Li","year":"2024","unstructured":"Li D, Huang Y, Lu H, Zhou S, Feng S, Li H, et al. Association between cognitive function, antioxidants, and clinical variables in Chinese patients with schizophrenia. BMC Psychiatry. 2024;24(1):912. https:\/\/doi.org\/10.1186\/s12888-024-06335-5.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"8210_CR50","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","volume":"37","author":"M San Ang","year":"2017","unstructured":"San Ang M, Abdul Rashid NA, Lam M, Rapisarda A, Kraus M, Keefe RSE, et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol. 2017;37(6):651\u201356. https:\/\/doi.org\/10.1097\/JCP.0000000000000790.","journal-title":"J Clin Psychopharmacol"},{"key":"8210_CR51","doi-asserted-by":"publisher","unstructured":"Tsoutsoulas C, Mulsant BH, Kumar S, Ghazala Z, Voineskos AN, Menon M, et al. Anticholinergic burden and Cognition in older patients with schizophrenia. J Clin Psychiatry. 2017;78(9):e1284\u2013e 1290. https:\/\/doi.org\/10.4088\/JCP.17m11523.","DOI":"10.4088\/JCP.17m11523"},{"issue":"11","key":"8210_CR52","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","volume":"11","author":"Y Stern","year":"2012","unstructured":"Stern Y. Cognitive reserve in ageing and Alzheimer\u2019s disease. The Lancet Neurol. 2012;11(11):1006\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(12)70191-6.","journal-title":"The Lancet Neurol"},{"issue":"4","key":"8210_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.37737\/ace.22013","volume":"4","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Yasunaga H. Theory and practice of propensity score analysis. ACE. 2022;4(4):101\u201309. https:\/\/doi.org\/10.37737\/ace.22013.","journal-title":"ACE"},{"issue":"10","key":"8210_CR54","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1176\/appi.ps.54.10.1395","volume":"54","author":"MF Brunette","year":"2003","unstructured":"Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric Serv. 2003;54(10):1395\u2013401. https:\/\/doi.org\/10.1176\/appi.ps.54.10.1395.","journal-title":"Psychiatric Serv"},{"issue":"3","key":"8210_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1176\/appi.ajp.20230075","volume":"181","author":"TW Rosenqvist","year":"2024","unstructured":"Rosenqvist TW, Wium-Andersen MK, Wium-Andersen IK, J\u00f8rgensen MB, Osler M. Long-term use of benzodiazepines and benzodiazepine-related drugs: a register-based Danish cohort study on determinants and risk of dose escalation. AJP. 2024;181(3):246\u201354. https:\/\/doi.org\/10.1176\/appi.ajp.20230075.","journal-title":"AJP"},{"issue":"8","key":"8210_CR56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, T\u00e4hk\u00e4p\u00e4\u00e4 S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns \u2013 a systematic review of register-based studies. Eur Psychiatr. 2015;30(8):1037\u201347. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.003.","journal-title":"Eur Psychiatr"},{"key":"8210_CR57","doi-asserted-by":"publisher","unstructured":"Taipale H, S\u00e4rkil\u00e4 H, Tanskanen A, Kurko T, Taiminen T, Tiihonen J, et al. Incidence of and characteristics associated with long-term benzodiazepine use in Finland. JAMA network open. JAMA Netw Open Open. 2020;3(10):e2019029. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.19029.","DOI":"10.1001\/jamanetworkopen.2020.19029"},{"key":"8210_CR58","doi-asserted-by":"publisher","unstructured":"Davies J, Rae TC, Montagu L. Long-term benzodiazepine and Z-drugs use in England: a survey of general practice. Br J Gen Pract. 2017;67(662):e609\u201313. https:\/\/doi.org\/10.3399\/bjgp17X691865.","DOI":"10.3399\/bjgp17X691865"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08210-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:02:28Z","timestamp":1784113348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8210"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08210-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8797752\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Shanghai Mental Health Center (2010\u201335). All participants provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"537"}}